Commercial anti-CD19 chimeric antigen receptor T-cell therapies (CART19) are efficacious against advanced B-cell non-Hodgkin lymphoma (NHL); however, most patients ultimately relapse. Several mechanisms contribute to this failure, including CD19-negative
Recent studies implicated the existence of adult lymphoid-primed multipotent progenitors (LMPPs) with little or no megakaryocyte-erythroid potential, quest... R M?Nsson,A Hultquist,S Luc,... - 《Immunity》 被引量: 580发表: 2007年 Induction of Early B Cell Factor (EBF) and Multiple B Linea...
×某群淋巴细胞表达率% ) 。T 细胞亚群 、B 细胞及 Chin J Clini Hepatol ,October 20 06 ,V o1.22 ,No.5 CD. CD 细胞表达率由 FACS Clibur 流式细胞仪 检测,用 Cell Quest 软件获取和分析 ;测定前用 BD 公司提供 的质控微球 ( 直径 5 Ixm) 调校仪器,以保证 ...
MvAMLLcells typesofB-Iinea辨ALL whilethe ratesin152 AMLwere posi石ve p“ents埘th 1Ile of on exDre8sionsCDl9蚰dCD20di如rentB—Une— very 7.2%arId low,011】v 2.O%,respectivelv. wereshowninTabk2,CDl9ex一 a辨ALLsubtvpes onal啪st ALL whdetlle 口ressed aⅡB.1ine醒esubtvpes ...